These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. New DTCA Guidance--Enough to Empower Consumers? Robertson CT N Engl J Med; 2015 Sep; 373(12):1085-7. PubMed ID: 26287748 [No Abstract] [Full Text] [Related]
4. Joint position paper on the regulatory approach to hematopoietic cell components in the United States. J Hematother; 1997 Apr; 6(2):91-2. PubMed ID: 9131437 [No Abstract] [Full Text] [Related]
5. Balancing Safety and Innovation for Cell-Based Regenerative Medicine. Marks P; Gottlieb S N Engl J Med; 2018 Mar; 378(10):954-959. PubMed ID: 29514023 [No Abstract] [Full Text] [Related]
6. Blood as a biological "drug": scientific, legal, and policy issues in the regulation of placental and umbilical cord stem cell transplantation. Kulynych J Univ Richmond Law Rev; 1998 Mar; 32(2):407-56. PubMed ID: 11657163 [No Abstract] [Full Text] [Related]
7. Stem cells. U.S. regulation of stem cells as medical products. Sipp D; Turner L Science; 2012 Dec; 338(6112):1296-7. PubMed ID: 23224541 [No Abstract] [Full Text] [Related]
8. Direct-to-consumer advertising of drugs. Weinmeyer R Virtual Mentor; 2013 Nov; 15(11):954-8. PubMed ID: 24257087 [No Abstract] [Full Text] [Related]
9. The dangers of unregulated stem-cell marketing. Mohammadi D Lancet; 2017 Oct; 390(10105):1823-1824. PubMed ID: 28870714 [No Abstract] [Full Text] [Related]
10. Regulation of dietary supplement advertising: current claims of interest to the Federal Trade Commission, Food and Drug Administration and National Advertising Division. Villafranco JE; Lustigman AB Food Drug Law J; 2007; 62(4):709-25. PubMed ID: 18557227 [No Abstract] [Full Text] [Related]
11. Effectively Regulating E-Cigarettes and Their Advertising--And the First Amendment. Lindblom EN Food Drug Law J; 2015; 70(1):55-92. PubMed ID: 26292472 [No Abstract] [Full Text] [Related]
12. Institute of Medicine's new drug safety report: implications for Canada. Cassels A CMAJ; 2006 Dec; 175(12):1515-6. PubMed ID: 17146086 [No Abstract] [Full Text] [Related]
13. FDA's proposed regulatory approach to regulation of hematopoietic stem/progenitor cell products. Harvath L Cytotherapy; 1999; 1(4):358-9. PubMed ID: 20440912 [No Abstract] [Full Text] [Related]
14. FDA regulation of stem-cell-based therapies. Halme DG; Kessler DA N Engl J Med; 2006 Oct; 355(16):1730-5. PubMed ID: 17050899 [No Abstract] [Full Text] [Related]
15. Hemacord approval may foreshadow regulatory creep for HSC therapies. Allison M Nat Biotechnol; 2012 Apr; 30(4):304. PubMed ID: 22491271 [No Abstract] [Full Text] [Related]
16. Drug risks and free speech--can Congress ban consumer drug ads? Shuchman M N Engl J Med; 2007 May; 356(22):2236-9. PubMed ID: 17476002 [No Abstract] [Full Text] [Related]
17. Umbilical cord blood stem cells: my body makes them, but do I get to keep them? Analysis of the FDA proposed regulations and the impact on individual constitutional property rights. Fredrickson JK J Contemp Health Law Policy; 1998; 14(2):477-502. PubMed ID: 9693489 [No Abstract] [Full Text] [Related]
18. The role of direct-to-consumer pharmaceutical advertising in patient consumerism. Wang B; Kesselheim AS Virtual Mentor; 2013 Nov; 15(11):960-5. PubMed ID: 24257088 [No Abstract] [Full Text] [Related]
19. FDA regulation of stem cell-based products. Fink DW Science; 2009 Jun; 324(5935):1662-3. PubMed ID: 19556496 [TBL] [Abstract][Full Text] [Related]
20. Direct-to-consumer advertising--strengthening our health care system. Holmer AF N Engl J Med; 2002 Feb; 346(7):526-8. PubMed ID: 11844858 [No Abstract] [Full Text] [Related] [Next] [New Search]